Thymosin Beta-4

Thymosin Beta-4 (Tβ4) is the most abundant member of the beta-thymosin family, a 43-amino-acid peptide present in virtually every nucleated cell in the human body. First isolated from bovine thymus in 1981 by Hannappel, Goldstein, and colleagues, Tβ4 has been characterized as a G-actin sequestering protein and a regulator of the actin cytoskeleton. Decades of preclinical work, primarily from Hynda Kleinman's group at the National Institute of Dental and Craniofacial Research, established its role in wound healing, angiogenesis, cardiac repair, and tissue regeneration. RegeneRx Biopharmaceuticals has pursued Phase 2 clinical trials in multiple indications. No Tβ4-based product has progressed to marketing approval. The synthetic heptapeptide TB-500 (amino acids 17-23 of Tβ4) is sold separately as a research chemical and is widely used in off-label sports recovery and biohacker contexts.

Discovery and Basic Biology

Thymosin Beta-4 was first isolated from bovine thymus extract in 1981 by Hannappel, Goldstein, and colleagues during efforts to characterize the thymic peptide fraction Thymosin Fraction 5. The protein was named for its origin (thymus) and its position in the family (beta-thymosin, second of the thymosin classes). Subsequent work showed that Tβ4 is not actually restricted to thymus tissue. It is expressed at high concentrations (up to 0.5 mM in some cell types) in virtually all human cells.

The full-length molecule consists of 43 amino acids. The amino terminal region contains the actin-binding domain. The peptide bond at positions 17-23 (sequence Ac-LKKTETQ) corresponds to a key bioactive region that was the basis for the synthetic fragment TB-500.

The Kleinman Group and the Core Mechanism

Over the 1990s and 2000s, Hynda Kleinman's group at the National Institute of Dental and Craniofacial Research (NIDCR) established much of the core biology of Tβ4. The principal findings:

• Tβ4 is a G-actin sequestering protein, binding monomeric actin and modulating the balance between G-actin (free monomers) and F-actin (polymerized filaments)
• Tβ4 accelerates wound healing in rodent models
• Tβ4 supports angiogenesis through Notch signaling
• Tβ4 promotes stem and progenitor cell migration to sites of injury
• Tβ4 reduces myofibroblast appearance, which reduces fibrosis and scarring

Goldstein and Kleinman in Annals of the New York Academy of Sciences in 2003 summarized over a decade of findings and described Tβ4 as "one of the most active wound-healing molecules" they had studied, with documented effects on dermal repair, corneal healing, hair follicle regeneration, and cardiac repair after injury.

Cardiac Epicardial Mobilization (Smart 2007)

A pivotal extension of the wound-healing biology came from Smart and colleagues in Nature in 2007. The paper demonstrated that Tβ4 induces adult epicardial progenitor mobilization and neovascularization in mouse models of myocardial infarction. The findings extended Tβ4's biology from dermal wound healing to cardiac repair and raised the possibility that endogenous Tβ4 modulation could be a strategy for treating ischemic heart disease.

This paper drove the RegeneRx cardiac program, which never produced a Phase 3 marketing approval but established preclinical proof of concept.

RegeneRx Clinical Trials

RegeneRx Biopharmaceuticals (now operating through licensing agreements) is the principal commercial sponsor of Tβ4 clinical development. The Phase 2 program included:

RGN-259 (topical Tβ4 eye drops):

• Indication: dry eye syndrome, neurotrophic keratopathy, corneal wound healing
• Phase 2 trials showed improvements in corneal staining scores and symptom relief versus placebo in subsets of patients
• Subsequent Phase 3 development has been pursued through partnerships including ReGenTree (US) and HLB Therapeutics (Korea)
• Has not produced an FDA approval as of 2026

RGN-137 (topical Tβ4 wound gel):

• Indication: pressure ulcers, venous stasis ulcers, epidermolysis bullosa
• Phase 2 trials showed statistically significant wound closure improvements in some endpoints
• Orphan drug designation for epidermolysis bullosa
• Has not produced an FDA approval

Cardiac program:

• Phase 2 trials initiated for acute myocardial infarction post-coronary intervention
• Did not produce sustained development

The general pattern: RegeneRx demonstrated safety and biological signal in Phase 2 but did not achieve the commercial development needed to reach Phase 3 marketing approval. Tβ4 is an active investigational compound rather than an approved drug.

IV Tβ4 in Healthy Volunteers

Crockford et al. Published in Annals of the New York Academy of Sciences in 2010 a randomized, placebo-controlled, single and multiple dose study of intravenous Tβ4 in healthy volunteers. The study established safety and pharmacokinetic characteristics of IV Tβ4 in humans. This remains one of the few well-controlled human pharmacokinetic studies of the full-length molecule.

The TB-500 Research-Chemical Market

Separately from the RegeneRx clinical program, a synthetic peptide marketed as TB-500 has become widely used in research-chemical and off-label sports-recovery contexts. The TB-500 sold in this market is typically the Ac-LKKTETQ heptapeptide, corresponding to amino acids 17-23 of Tβ4 (sometimes with N-terminal acetylation).

Important caveats:

• TB-500 is not chemically identical to the full-length Tβ4 used in RegeneRx trials
• There are no published human clinical trials of the TB-500 fragment specifically
• Identity and purity of marketed TB-500 products are often not verified
• The assumption that the 7-amino-acid fragment captures the full biological activity of the 43-amino-acid parent peptide is plausible but not rigorously established
• TB-500 has its own separate article on PeptScope (TB-500)

Regulatory Status

• FDA: Not approved for any indication. IND status for various RegeneRx formulations.
• EMA: Not approved
• WADA: Banned at all times in all sports under Section S2 (Peptide Hormones, Growth Factors, Related Substances) since 2011. Detection methods validated.
• Horse racing: Banned by major racing authorities. Testing methods developed
• Compounding pharmacy: Tβ4 appears on FDA Section 503A bulk substance evaluations. Compounding pharmacies have offered Tβ4 and TB-500 preparations, but their status under 503A bulk substance regulations has been contested. FDA has issued enforcement actions against some compounders selling TB-500 or Tβ4.

Thymosin Beta-4 acts through several characterized molecular mechanisms, all flowing from its primary biology as an actin-binding peptide.

Primary Mechanism: G-Actin Sequestration

Tβ4 is the principal G-actin sequestering protein in mammalian cells. It binds monomeric G-actin (the unpolymerized form) via its N-terminal binding domain in a 1:1 ratio. This binding modulates the G-actin / F-actin equilibrium, regulating the polymerization status of the actin cytoskeleton.

This regulation has functional consequences:

• Cell migration: actin polymerization at the leading edge of migrating cells drives cellular movement. Tβ4 modulates this process during wound healing and stem cell mobilization
• Wound closure: keratinocyte migration to close epithelial wounds depends on regulated actin dynamics
• Tissue remodeling: fibroblast and myofibroblast behavior in the remodeling phase of wound healing depends on actin cytoskeleton organization

The actin binding is the molecular foundation. The downstream biological effects of Tβ4 in different tissues largely reflect how different cell types respond to modulated actin dynamics.

Stem and Progenitor Cell Mobilization

Tβ4 mobilizes bone marrow-derived stem cells and tissue-resident progenitor cells to sites of injury. In the cardiac context (Smart 2007), Tβ4 activates epicardial progenitor cells in adult mice, restoring an embryonic-like progenitor population that can differentiate into endothelial cells, smooth muscle cells, and cardiomyocyte-supportive cell types.

In dermal wound healing, Tβ4 mobilizes bone marrow-derived cells that contribute to wound repair. The cellular biology is complex and the exact identity of all the mobilized populations remains under investigation.

Angiogenesis (Notch Pathway)

Tβ4 promotes angiogenesis (new blood vessel formation) in part through Notch signaling in endothelial cells. The mechanism is incompletely characterized but involves Tβ4 binding to integrin-linked kinase (ILK) and modulating downstream signaling cascades that affect endothelial sprouting and tube formation.

This angiogenic effect is relevant to wound healing (where new blood vessels are required for tissue repair), to cardiac repair (where collateral vessel formation can mitigate ischemic damage), and theoretically to oncology (where it represents a safety concern, since some cancers depend on angiogenesis).

Anti-Inflammatory Effects

Tβ4 reduces pro-inflammatory cytokine expression and suppresses inflammatory signaling during the repair phase of wound healing. Mechanisms include:

• Reduced NF-κB activation
• Reduced IL-6, TNF-α, IL-1β expression
• Reduced myeloperoxidase activity at wound sites
• Reduced reactive oxygen species

The anti-inflammatory effect is one of the principal explanations for Tβ4's broad tissue-protective activity in injury models.

Anti-Apoptotic and Anti-Fibrotic Effects

Tβ4 reduces apoptosis in injured cardiomyocytes, corneal epithelial cells, and other injured cell populations. The mechanism involves upregulation of Bcl-2 family anti-apoptotic proteins and reduced caspase activation.

Tβ4 reduces myofibroblast appearance and reduces scar tissue formation, particularly in cardiac and dermal injury models. This anti-fibrotic effect distinguishes Tβ4 from some other growth factors that accelerate healing but produce more scarring.

Hair Follicle Stem Cell Activation

Tβ4 activates hair follicle stem cells in animal models, promoting hair growth. This has motivated investigation in alopecia, though no clinical product has emerged.

Effects in animal and cell-culture models (extensive preclinical evidence base):

• Accelerated dermal wound healing
• Accelerated corneal epithelial healing
• Reduced infarct size in cardiac ischemia/reperfusion models
• Improved cardiac function recovery after myocardial infarction
• Promoted neurogenesis in stroke and TBI models
• Improved functional recovery in stroke models
• Reduced scarring and fibrosis
• Promoted hair follicle stem cell activation
• Enhanced angiogenesis in ischemic tissue
• Improved tendon and ligament repair (rodent models)
• Improved diabetic wound healing
• Reduced reactive oxygen species and inflammatory markers

Effects in human clinical trials (RegeneRx Phase 2 programs):

• Dry eye / corneal healing (RGN-259): improved corneal staining scores, reduced symptoms in subsets of patients
• Dermal ulcers (RGN-137): improved wound closure in some endpoints
• Cardiac ischemia: safety established, efficacy not advanced
• IV Tβ4 in healthy volunteers: well-tolerated, pharmacokinetic profile established

Effects in off-label sports-recovery and biohacker contexts (uncontrolled, anecdotal):

• Subjective improvement in chronic joint issues (knees, shoulders, elbows, hips)
• Faster recovery from acute injuries
• Improved tendon and ligament recovery
• Reduced inflammation in chronic joint conditions
• Frequently combined with BPC-157 ("Wolverine Stack") for synergistic claims

Honest evidence framing: the preclinical evidence base for Tβ4 is broader and stronger than for most peptides used in regenerative medicine contexts. The human clinical evidence base is meaningful (RegeneRx Phase 2 programs) but has not produced an FDA approval. The off-label TB-500 use in sports recovery is supported by extensive animal data and anecdotal user reports but does not have controlled human trial validation specific to the heptapeptide fragment sold as TB-500.

Important note: there is no FDA-approved dosing protocol for Tβ4 or TB-500 outside of investigational use. The doses described below are from RegeneRx clinical trials and off-label community protocols, not validated for general therapeutic use.

RegeneRx clinical trial doses (full-length Tβ4):

• RGN-259 eye drops: 0.1 percent Tβ4 ophthalmic solution, applied 4 to 6 times daily
• RGN-137 wound gel: 0.01 to 0.03 percent topical Tβ4 gel, applied daily to the wound bed
• IV Tβ4 (Crockford 2010): single and multiple dose escalation studies up to 1260 mg

Off-label TB-500 community protocols (heptapeptide fragment, not full-length Tβ4):

• Loading phase: 5 mg subcutaneously per week for 4 to 6 weeks, sometimes split as 2.5 mg twice weekly
• Maintenance phase: 5 mg every 2 to 4 weeks
• Acute injury protocol: 5 to 10 mg per week for 2 to 6 weeks
• Stacking with BPC-157: variable, typically 5 mg TB-500 weekly + 250 to 500 mcg BPC-157 daily

Routes:

• Subcutaneous is the most common off-label route
• Intramuscular near injury sites is sometimes used
• IV use exists in clinical research but is not common in off-label contexts
• Topical formulations (RegeneRx products) for specific eye and skin indications

Reconstitution and storage:

• Lyophilized peptide reconstituted with bacteriostatic water or 0.9 percent sodium chloride
• Refrigeration after reconstitution
• Stability of reconstituted peptide: typically 3 to 4 weeks at 2 to 8°C
• Vendor quality varies substantially in the research-chemical market

Special populations:

• Pregnancy and breastfeeding: not studied. Avoid
• Pediatric: not approved or studied
• Active cancer: theoretical contraindication due to angiogenic and pro-migratory effects (see Side Effects)
• Athletes subject to anti-doping testing: WADA-prohibited at all times
• Renal/hepatic impairment: limited data

Acute and short-term adverse effects (from RegeneRx trial data and off-label user reports):

• Injection-site reactions (mild redness, transient pain)
• Mild fatigue or lethargy at high doses
• Headache (occasional)
• Mild flushing
• Transient nausea (uncommon)

Serious adverse effects in clinical trial populations have been rare. The Crockford 2010 IV dose-escalation study did not report serious safety signals up to 1260 mg.

Theoretical concerns requiring monitoring:

• Cancer risk and progression: Tβ4 promotes angiogenesis, stem cell mobilization, and cell migration, all of which are biological processes that some cancers exploit. Tβ4 overexpression has been associated with aggressive tumor behavior in some cancer types (hepatocellular carcinoma, melanoma, breast cancer). The relationship between exogenous Tβ4 administration and cancer risk in humans is not well characterized. Active or recent cancer is a theoretical contraindication.
• Effects on existing vascular pathology: angiogenesis modulation could theoretically affect proliferative retinopathy or other neovascular eye conditions. Caution with active proliferative diabetic retinopathy.
• Immunogenicity: long-term repeated administration of any peptide can produce anti-drug antibodies. The clinical relevance of antibodies to Tβ4 has not been well characterized in humans.
• Stem cell mobilization in unintended contexts: the mobilization effects could theoretically affect other proliferative conditions.

Pregnancy and breastfeeding: avoid. No human reproductive data.

Pediatric: not approved or studied. Avoid in patients under 18 outside research contexts.

WADA prohibition (athletes): Tβ4 and TB-500 are banned at all times in all sports under Section S2. Detection methods validated. Use carries substantial risk of doping violation regardless of therapeutic intent.

Quality concerns specific to TB-500 research-chemical market:

• Identity verification often absent
• Purity not consistently characterized
• Endotoxin contamination possible with non-pharmaceutical-grade products
• Bacterial contamination risk with home reconstitution
• Vendor reliability varies substantially

Thymosin Beta-4 sits at the center of the regenerative-peptide category alongside BPC-157 and GHK-Cu. Its closest comparators by mechanism or use:

• TB-500: the synthetic heptapeptide fragment of Tβ4. Same general use case, different chemistry, less rigorous identity verification in the research-chemical market. See the TB-500 article for the off-label dosing and sports-recovery focus specifically.
• BPC-157: synthetic gastric peptide with overlapping wound-healing profile. Different mechanism (NO-pathway modulation, VEGFR2 signaling, gut-specific origin) but similar tissue-repair claims. Most commonly stacked with Tβ4/TB-500 in the "Wolverine Stack."
• GHK-Cu: copper tripeptide with regenerative and anti-aging effects. Different mechanism (copper transport, fibroblast modulation) but partially overlapping use cases in tissue repair, skin, and hair contexts.
• Pentadeca-arginate (PDA): modified BPC-157 analog with reported enhanced stability and similar tissue-repair claims. Less established research base than BPC-157 or Tβ4.

Common stacks circulating in sports-recovery communities:

• TB-500 + BPC-157 (Wolverine Stack): by far the most popular combination. Rationale: TB-500 acts systemically and concentrates at injury sites. BPC-157 acts more locally on gut-derived and connective-tissue pathways. Typical dosing: TB-500 5 mg weekly + BPC-157 250-500 mcg daily. No controlled human trials.
• TB-500 + GHK-Cu: for combined tissue repair and skin/hair effects. Less commonly used than the Wolverine Stack. No controlled evidence.
• TB-500 + Growth Hormone Secretagogues (CJC-1295, Ipamorelin): for combined tissue repair and IGF-1-mediated muscle building. Common in performance contexts. No controlled trial evidence.
• TB-500 + PEMF or other physical therapies: rationale of combining biological tissue-repair signals with mechanical rehabilitation. No controlled evidence.

Combinations to avoid or use with caution:

• Active or recent cancer: see Side Effects. Theoretical contraindication.
• Active proliferative retinopathy: caution due to angiogenic effects
• Pregnancy and breastfeeding: avoid
• Athletes subject to WADA testing: TB-500 use is a doping violation regardless of therapeutic intent
• Active vascular conditions with neovascularization concerns: caution

The most actionable framing of Thymosin Beta-4 in 2026: this is one of the best-characterized regenerative peptides at the preclinical level, with a meaningful but limited human clinical trial base (RegeneRx Phase 2 programs) that has not yet produced an FDA approval. The TB-500 heptapeptide fragment sold separately in the research-chemical market is widely used off-label for tissue recovery, particularly tendon and ligament issues that have plateaued with standard rehabilitation. The evidence supporting off-label use is animal data, mechanism, and anecdotal user reports, not controlled human trials of the fragment specifically. Athletes subject to WADA testing should not use Tβ4 or TB-500 under any circumstances. The cancer-pathway considerations warrant caution in any individual with current or recent malignancy.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.